Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegargiminase - Polaris Pharmaceuticals

Drug Profile

Pegargiminase - Polaris Pharmaceuticals

Alternative Names: ADI-PEG; ADI-PEG 20; ADI-SS PEG; Arginine deiminase pegylated; Arginine deiminase-PEG; Hepacid; Melanocid; PEG arginine deiminase; Pegylated arginine deiminase - Polaris Group

Latest Information Update: 26 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phoenix Pharmacologics
  • Developer Barts and The London School of Medicine and Dentistry; Memorial Sloan-Kettering Cancer Center; Polaris Pharmaceuticals; University of Miami; Washington University School of Medicine
  • Class Antineoplastics; Hepatoprotectants; Hydrolases; Polyethylene glycols; Proteins; Radiosensitisers
  • Mechanism of Action Arginine deiminase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant-mesothelioma; Liver cancer; Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Malignant-mesothelioma
  • Phase III Leiomyosarcoma; Liver cancer; Soft tissue sarcoma
  • Phase II/III Glioblastoma
  • Phase II Acute myeloid leukaemia; Malignant melanoma; Non-alcoholic steatohepatitis; Non-Hodgkin's lymphoma; Small cell lung cancer
  • Phase I Head and neck cancer
  • No development reported Bladder cancer; Breast cancer; Cancer; Gastrointestinal cancer; Lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Uveal melanoma; Viral infections

Most Recent Events

  • 22 Dec 2023 Pegargiminase - Polaris Pharmaceuticals is available for licensing as of 22 Dec 2023. https://polarispharma.com/about-us/?lang=en
  • 30 Nov 2023 Phase-II clinical trials in Non-alcoholic steatohepatitis in Taiwan (IM, Injection) (NCT05842512)
  • 29 Nov 2023 Phase-III clinical trials in Leiomyosarcoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT05712694)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top